Detail akcie Immunic Rg online

Business Summary: Immunic, Inc. is a biotechnology company developing a clinical pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The Company is engaged in pursuing clinical development of programs, which include the vidofludimus calcium (IMU-838) program, which is in Phase III clinical development for patients with relapsing multiple sclerosis (RMS), and which has shown therapeutic activity in Phase II clinical trials in patients suffering from relapsing-remitting MS, progressive MS and moderate-to-severe ulcerative colitis; the IMU-856 program, which is targeted to regenerate bowel epithelium and restore intestinal barrier function, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, Graft-versus-Host-Disease and weight management, and the IMU-381 program, which is a molecule being developed to specifically address the needs of gastrointestinal diseases.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Immunic Inc revenues was not reported. Net loss increased 3% to $77.9M. Higher net loss reflects Biopharmaceutical segment loss increase of 10% to $79.9M. Basic Earnings per Share excluding Extraordinary Items increased from -$0.76 to -$0.59.